Smith+Nephew (NYSE: SNN) Reports Significant Recovery Improvement with REGENETEN Implant

April 9, 2026

Key Developments Smith+Nephew (NYSE: SNN) announced promising results from the first randomized control trial evaluating its REGENETEN◊ bioinductive implant for partial-thickness rotator cuff repair. The study revealed a notable reduction in post-operative recovery times, effectively halving the duration patients typically undergo rehabilitation. The data also highlighted high healing rates associated with the REGENETEN implant, underscoring its potential to improve surgical outcomes for patients with this common shoulder injury. These findings…

Read More >>